Merial was a multinational animal health company in Lyon, France. It was founded in 1997 as a joint venture between Merck & Co. and Sanofi-Aventis. In January 2017, Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets.[1]
Overview
In August 1997, Merial started as a joint venture between the animal health subsidiaries of Merck & Co. (MSD AgVet) and Sanofi-Aventis (Rhône-Mérieux). Merial became the animal health division of Sanofi, when Sanofi bought out Merck's 50% share of the joint venture. On December 30, 2016 Boehringer Ingelheim completed a swap of their OTC business for Sanofi's animal health business. Merial is now owned by Boehringer Ingelheim and combined with their animal health business, Boehringer Ingelheim Vetmedica, to form Boehringer Ingelheim Animal Health.
Merial produces many products and vaccines for domestic pets, farm animals and wildlife. Merial has about 6,900 employees and is present in more than 150 countries in the world.[2] Their sales in 2015 were about €2.5 billion.[3] Some of Merial's most popular products are Frontline, Heartgard, NexGard, Ivomec, PureVax and Previcox.
In October 2009, Merial announced it was investing 70 million US$ at its poultry vaccines plant in Nanchang Hi-tech Development Zone, China. On March 9, 2010, Sanofi-Aventis announced[4] it had exercised an option to combine Merial with Intervet/Schering Plough, the animal health business of Merck. The new joint venture would be equally owned by Merck and Sanofi-Aventis. On March 22, 2011, they announced the mutual termination of their agreement to form a new animal health joint venture.
Investigations
Merial was investigated in connection with a 2007 United Kingdom foot-and-mouth outbreak, after a strain of foot-and-mouth disease alleged to have been sourced from one of their research facilities was found at Pirbright, a farm in Surrey, England, in August 2007.[5] The investigators concluded that "release was most likely due to escape of live virus from the drainage system that connects the vaccine production plant to the sodium hydroxide treatment tanks on another part of the Pirbright site."[6]
The two independent inquiries found that Merial complied with all regulations and committed no breaches of biosecurity.
In 2016, the NOAH Code of Practice Committee found Merial Animal Health to be in breach of 2 out of 4 items under complaint. This related to the promotion of NexGard Spectra® to the veterinary profession by both account managers and technical teams via telephone conversations and webinars from February 2016 onwards.[7]
External links
References
- Boehringer Ingelheim Closes Deal to Acquire Merial www.bovinevetonline.com, retrieved 2017-01-10^
- Company merial.com, retrieved 2015-11-03^
- Sanofi - Key facts & figures en.sanofi.com, retrieved 2015-11-03^
- Sanofi-aventis and Merck to create a Global Leader in Animal Health March 8, 2010, retrieved November 3, 2015^
- Initial report on potential breaches to biosecurity at the Pirbright site, 2007 UK Health and Safety Executive, May 12, 2008, retrieved 2009-04-22^
- National Emergency Epidemiology Group. FMD in Surrey, UK, 2007: Epidemiology report on the probable release of FMD virus at the Pirbright site and the transmission of infection to the first infected cattle herd, from investigations up to 29 August 2007 (Day 26) UK Department for Environment, Food and Rural Affairs (DEFRA), 29 August 2007, retrieved 2009-04-22^
- Merial Animal Health found in breach of NOAH Code on Promotion NOAH (National Office of Animal Health), 2016-08-19, retrieved 2019-12-11^